Bolaños CA

Language: Spanish
References: 19
Page: 295-300
PDF size: 120.63 Kb.

ABSTRACT

Aplastic anemia is a haemotopoietic stem-cell disorder that results in pancitopenia and hypocellular bone marrow. According to its etiology, it can be congenital or acquired. The pathophysiology of acquired aplastic anemia is immune mediated. Environmental exposures, such as drugs, toxins or viruses, are thought to trigger the aberrant immune response that eliminates the bone marrow stem-cells; besides, most cases are classified as idiopathic. In this review, I expose the case of a patient with pancitopenia and aplastic anemia, the causes of acquired aplastic anemia, its physiopathological mechanisms, diagnostic criteria, differential diagnosis and possibilities of treatment.

REFERENCES

1. Arranz R, Bendaña A, Bueno J, et al. Protocolo de Diagnóstico y Tratamiento de la Aplasia Medular. Asociación Española de Hematología y Hemoterapia, Subcomité de Aplasia Medular del Grupo Español de Trasplante de Progenitores Hematopoyéticos 2001: 1-12. http://www.carloshaya.net/uchematologia/media/aplasia.pdf. Consultada 26 de noviembre de 2010.

2. Bacigalupo A, Passweg J. Diagnosis and Treatment of Acquired Aplastic Anemia. Hematol Oncol Clin N Am 2009; 23: 159–170.

3. Bagby GC, Meyers G. Myelodysplasia and Acute Leukemia as Late Complications of Marrow Failure: Future Prospects for Leukemia Prevention. Hematol Oncol Clin N Am 2009 23: 361–376.

4. Bakhshi S, Abella E. Aplastic Anemia. Hematology, Red Blood Cells and Disorders. Emedicine Octubre 2010. http://www.imedicine.com/DisplayTopic.asp?bookid=6&topic=162. Consultada el 26 de noviembre de 2010.

5. Brodsky RA, Jones RJ. Aplastic anaemia. Lancet 2005; 365: 1647–56.

6. Caja Costarricense de Seguro Social, Dirección de Farmacoepidemiología, Área de Medicamentos y Terapéutica Clínica. Formulario Terapéutico Institucional para el Primer Nivel de Atención en Salud. 2008; 13, 29, 53, 181, 185, 188, 222.

7. FDA Center for Drug Evaluation and Research, Lasix ® Furosemide. 2010; 1-9. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/016273s061lbl.pdf. Accesada 29 de noviembre de 2010.

8. Guinan EC. Acquired Aplastic Anemia in Children. Hematol Oncol Clin N Am 2009; 23: 171–191.

9. Hirano N, Butler MO, von Bergwelt- Baildon M, et al. Autoantibodies frequently detected in patients with aplastic anemia. Blood 2003; 102(13): 4567-4575.

10. Jha A, Sayami G, Adhikari RC, Panta AD, Jha R. Bone Marrow Examination in Cases of Pancytopenia. J Nepal Med Assoc 2008; 47(169):12-7.

11. Kelly JP, Kaufman DW, Shapiro S. Risks of agranulocytosis and aplastic anemia in relation to the use of cardiovascular drugs: The International Agranulocytosis and Aplastic Anemia Study. Clin Pharmacol Ther. 1991; 49(3): 330-341.

12. Malik S, Sarwar I, Mehmood T, Naz F. Aetiological Considerations of Acquired Aplastic Anemia. J Ayub Med Coll Abbottabad 2009; 21(3): 127-130.

13. Mintzer DM, Billet SN, Chmielewski L. Drug-Induced Hematologic Syndromes. Advances in Hematology 2009; Article ID 495863: 1-11.

14. Scheinberg P, Cooper JN, Sloand EM, et al. Association of Telomere Length of Peripheral Blood Leukocytes with Hematopoietic Relapse, Malignant Transformation, and Survival in Severe Aplastic Anemia. JAMA 2010; 304(12): 1358-1364.

15. Schick P. Megaloblastic Anemia. Hematology, Red Blood Cells and Disorders. Emedicine Octubre 2010. http://www.imedicine.com/DisplayTopic.asp?bookid=6&topic=1420. Consultada el 26 de noviembre de 2010.

16. Solomou E, Gibellini F, Stewart B, et al. Perforin gene mutations in patients with acquired aplastic anemia. Blood 2007; 109(12): 5234-5237.

17. Wolverton S, Remlinger K. Suggested Guidelines for Patient Monitoring: Hepatic and Hematologic Toxicity Attributable to Systemic Dermatologic Drugs. Dermatol Clin 2007: 25; 195–205.

18. Young N. Acquired Aplastic Anemia. JAMA 1999; 282(3): 271-278.

19. Young N, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 2006; 108: 2509-2519.